Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).
Thomas E. Hutson
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer
Honoraria - AVEO; Bayer; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer
Research Funding - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Dmitry Nosov
No relevant relationships to disclose
Timothy Eisen
Consultant or Advisory Role - Astellas Pharma (U); AVEO; AVEO (U); Bayer Schering Pharma; GlaxoSmithKline; Pfizer; Roche
Stock Ownership - AstraZeneca; AstraZeneca
Honoraria - AVEO; Bayer; Bayer; GlaxoSmithKline; GlaxoSmithKline; Pfizer; Pfizer; Roche
Research Funding - AstraZeneca; Bayer; Bayer; GlaxoSmithKline; GlaxoSmithKline; Pfizer; Pfizer
Oleg N. Lipatov
No relevant relationships to disclose
Piotr Tomczak
No relevant relationships to disclose
Anna Alyasova
No relevant relationships to disclose
Mihai Harza
No relevant relationships to disclose
Mikhail Kogan
Research Funding - AVEO
Boris Y. Alexseev
Research Funding - AVEO
Cezary Szczylik
Consultant or Advisory Role - AVEO
Andrew Louis Strahs
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Brooke Esteves
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Anna Berkenblit
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - AVEO; GlaxoSmithKline; Pfizer